Ascension Sciences Receives Import Permit from Health Canada

VANCOUVER, December 17th, 2020 — Ascension Sciences Inc. (“Ascension Sciences”, “Ascension” or “ASI”), an independent laboratory focused on nanoparticle formulation development for cannabinoid therapeutics, is pleased to announce that it has been issued an Import Permit by Health Canada.

The permit is effective immediately and will allow ASI, one of Canada’s few third-party cannabis Contract Researchers for formulation development, to accept shipments of cannabinoids for nanoparticle research. Approved cannabinoids included in the importation are Delta9-THC, CBD, and other minor cannabinoids.

“Issuance of this permit from Health Canada further solidifies Ascension Sciences’ position as a key research resource for groups looking to formulate and collaborate on nanoparticle delivery of cannabinoid therapeutics,” stated Tomas Skrinskas, Founder & CEO of Ascension Sciences. 

For service and media inquiries, please contact [email protected]. Stay connected with ASI on LinkedIn and Twitter for the latest news.


About Ascension Sciences

Employing nanoparticle formulation technology from the cutting edge of genetic medicine, Ascension Sciences Inc. (ASI) is developing cannabinoid nano delivery platforms and techniques for the pharma and nutraceutical industries. ASI’s R&D and formulation development services are an efficient option for research driven firms that require the advantages of nanoparticle delivery for their active ingredients. 

For more information, please visit